Logo of dddtDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressDrug Design, Development and Therapy
PMC full text:
Copyright/LicenseRequest permission to reuse

Figure 7

An external file that holds a picture, illustration, etc. Object name is dddt-9-2887Fig7.jpg

AT-101 plus CDDP does not affect expression levels of APE1/Ref-1 in A549 cells determined by Western blotting assay.

Notes: (A) Representative gel blots showing expression levels of APE1/Ref-1 in A549 cells treated with vehicle control, 5 μM CDDP, 5 μM AT-101, or 5 μM AT-101 plus 5 μM CDDP. (B) Bar graph showing the relative level of APE1/Ref-1 in A549 cells treated with vehicle control, 5 μM CDDP, 5 μM AT-101, or 5 μM AT-101 plus 5 μM CDDP. An equal amount of protein samples was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred onto a polyvinylidene difluoride membrane. APE1/Ref-1 was probed using the primary antibody and visualized using the enhanced chemiluminescence. β-actin was used as the internal control for blot densitometric normalization. Data are the mean ± standard deviation of three independent experiments and analyzed by one-way analysis of variance.

Abbreviations: APE1, apurinic/apyrimidinic endonuclease 1; CDDP, cisplatin; Ref-1, redox effector factor 1.

Images in this article

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
  • Figure 6
  • Figure 7
  • Figure 8
  • Figure 9
  • Figure 10
  • Figure 11
  • Figure 12
  • Figure 13
  • Figure 14
Click on the image to see a larger version.